Literature DB >> 8637624

[3H]Nisoxetine binding sites in the cat brain: an autoradiographic study.

Y Charnay1, L Leger, P G Vallet, P R Hof, M Jouvet, C Bouras.   

Abstract

The binding of [3H]nisoxetine, a selective inhibitor of the high-affinity noradrenaline uptake sites, was studied on frontal frozen sections of the cat brain. The highest densities in autoradiographic signal were observed in the nucleus locus coeruleus and its ascending pathways, in the area postrema and in the dorsal part of the inferior olive, the pontine nuclei, the raphe nuclei, the colliculi, the periventricular and lateral areas of the hypothalamus, the suprachiasmatic nucleus, the nucleus accumbens and the olfactory bulb. A moderately high concentration of binding sites was observed in the hippocampal formation, especially in the molecular layer of Ammon's horn, in the superficial layers of the entorhinal cortex and in the indusium griseum. Binding sites were visualized in all the subdivisions of the neocortex. The highest density of binding was generally detected in the outer edge of the superficial layer I. In some cortical areas, especially in the visual cortex, labeling with a prevalent laminar distribution in the superficial layers I-III and in the deep layers V-VI was clearly observed. Moderate to low densities of binding sites were seen in most other areas of the brain except in the white matter, the caudate nucleus and putamen, which were devoid of labeling. Overall these findings indicate a good correlation between the distribution of [3H]nisoxetine binding sites and the noradrenergic systems. Furthermore, data suggest that in several areas, high-affinity noradrenaline reuptake mechanisms could play an important role in local interactions between the noradrenergic system and the other monoaminergic systems.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8637624     DOI: 10.1016/0306-4522(95)00257-j

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  6 in total

1.  Synthesis and positron emission tomography evaluation of three norepinephrine transporter radioligands: [C-11]desipramine, [C-11]talopram and [C-11]talsupram.

Authors:  Magnus Schou; Judit Sóvágó; Victor W Pike; Balázs Gulyás; Klaus P Bøgesø; Lars Farde; Christer Halldin
Journal:  Mol Imaging Biol       Date:  2006 Jan-Feb       Impact factor: 3.488

2.  Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2.

Authors:  Nicholas Seneca; Balázs Gulyás; Andrea Varrone; Magnus Schou; Anu Airaksinen; Johannes Tauscher; Francois Vandenhende; William Kielbasa; Lars Farde; Robert B Innis; Christer Halldin
Journal:  Psychopharmacology (Berl)       Date:  2006-08-04       Impact factor: 4.530

3.  The NH(2)-terminus of norepinephrine transporter contains a basolateral localization signal for epithelial cells.

Authors:  H H Gu; X Wu; B Giros; M G Caron; M J Caplan; G Rudnick
Journal:  Mol Biol Cell       Date:  2001-12       Impact factor: 4.138

4.  In vivo assessment of [11C]MRB as a prospective PET ligand for imaging the norepinephrine transporter.

Authors:  Alin J Severance; Matthew S Milak; J S Dileep Kumar; Jaya Prabhakaran; Vattoly J Majo; Norman R Simpson; Ronald L Van Heertum; Victoria Arango; J John Mann; Ramin V Parsey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-19       Impact factor: 9.236

5.  (R)-N-Methyl-3-(3'-[F]fluoropropyl)phenoxy)-3-phenylpropanamine (F-MFP3) as a potential PET imaging agent for norepinephrine transporter.

Authors:  Vivien L Nguyen; Rama Pichika; Paayal H Bhakta; Ritu Kant; Jogeshwar Mukherjee
Journal:  J Labelled Comp Radiopharm       Date:  2010-02-09       Impact factor: 1.921

6.  fMRI of cocaine self-administration in macaques reveals functional inhibition of basal ganglia.

Authors:  Joseph B Mandeville; Ji-Kyung Choi; Bechir Jarraya; Bruce R Rosen; Bruce G Jenkins; Wim Vanduffel
Journal:  Neuropsychopharmacology       Date:  2011-02-09       Impact factor: 7.853

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.